Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcgamma receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
Purity:
95.00%
CAS Number:
[1858168-59-8]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
